

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM838981

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	ASSIGNMENT OF THE ENTIRE INTEREST AND THE GOODWILL		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
PLx Pharama Inc.		05/26/2023	Corporation: DELAWARE
PLx Opco Inc.		05/26/2023	Corporation: DELAWARE
RECEIVING PARTY DATA			
Name:	PLx Acquisition Company, LLC		
Street Address:	4455 Genesee Street		
City:	Buffalo		
State/Country:	NEW YORK		
Postal Code:	14225		
Entity Type:	Limited Liability Company: DELAWARE		
PROPERTY NUMBERS Total: 11			
Property Type	Number	Word Mark	
Registration Number:	6810135	ASPIRIN MADE AMAZING!	
Registration Number:	6688135	ASPIRIN THERAPY VAZALORE	
Registration Number:	6672405	FIRST LIQUID-FILLED ASPIRIN CAPSULES	
Registration Number:	6805044	HEART PROTECTION WITH YOUR STOMACH IN MI	
Registration Number:	5128399	PLX	
Registration Number:	6591723	PLX PHARMA INC.	
Serial Number:	90165649	PLXGUARD	
Registration Number:	6591111	VAZALORE	
Registration Number:	6591629	VAZALORE	
Registration Number:	6782829		
Registration Number:	6732291		
CORRESPONDENCE DATA			
Fax Number:			
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Email:	TMDocket@us.dlapiper.com		
Correspondent Name:	Carissa L. Bouwer, Esq.		
Address Line 1:	555 Mission Street, Suite 2400		
Address Line 4:	San Francisco, CALIFORNIA 94105-2933		

CH \$290.00 6810135

NAME OF SUBMITTER:	Carissa L. Bouwer, Esq.
SIGNATURE:	/Carissa Bouwer/
DATE SIGNED:	09/13/2023
Total Attachments: 5 source=MPG - PLx Trademark (TM) Assignment Agreement [Fully Executed - 5-26-2023]#page1.tif source=MPG - PLx Trademark (TM) Assignment Agreement [Fully Executed - 5-26-2023]#page2.tif source=MPG - PLx Trademark (TM) Assignment Agreement [Fully Executed - 5-26-2023]#page3.tif source=MPG - PLx Trademark (TM) Assignment Agreement [Fully Executed - 5-26-2023]#page4.tif source=MPG - PLx Trademark (TM) Assignment Agreement [Fully Executed - 5-26-2023]#page5.tif	

TRADEMARK ASSIGNMENT AGREEMENT

This Trademark Assignment Agreement (this "Trademark Assignment") dated as of May 26, 2023 (the "Effective Date") is made by and among between PLx Pharma Inc., a Delaware corporation (the "Company"), and PLx Opco Inc., a Delaware corporation and a wholly-owned subsidiary of the Company (together with the Company, "Assignors" and each, an "Assignor"), and PLx Acquisition Company, LLC, a Delaware limited liability company ("Assignee"). All capitalized terms used but not otherwise defined in this Trademark Assignment will have the meanings ascribed to such terms in the Asset Purchase Agreement (defined below) and the rules of construction set forth in the Asset Purchase Agreement will be applied wherever appropriate herein.

WHEREAS, Assignors are the owners of the trademarks identified in Schedule A ("Assigned Trademarks") and desire to assign to Assignee all of their rights, titles and interests in, to and under the Assigned Trademarks, together with the goodwill and business symbolized thereby;

WHEREAS, Assignee desires to obtain all of Assignors' rights in, to and under the Assigned Trademarks;

WHEREAS, pursuant to that certain Asset Purchase Agreement dated as of April 12, 2023 (as amended from time to time, the "Asset Purchase Agreement"), between Assignee and Assignors, Assignors have agreed, among other things, to assign all of their rights, titles and interests in, to and under the Assigned Trademarks to Assignee, and Assignee has agreed to accept such assignment; and

WHEREAS, this Trademark Assignment will be executed in connection with the Closing under the Asset Purchase Agreement, as required thereby.

NOW, THEREFORE, in consideration of the premises and covenants set forth herein and in the Asset Purchase Agreement and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending to be legally bound, hereby agree as follows:

1. Each Assignor hereby sells, assigns, transfers, conveys and delivers to Assignee all of such Assignor's right, title and interest in, to and under the Assigned Trademarks, together with the goodwill of the business symbolized or embodied therein, including the right to recover for past infringement, whether arising prior to or subsequent to the Effective Date.
2. Each Assignor authorizes and requests that the United States Patent and Trademark Office, and the corresponding entities or agencies in any foreign countries or multinational authorities (as applicable), record Assignee as the owner of the Assigned Trademarks. These obligations shall be binding upon each Assignor's successors, assigns, heirs, executives, administrators, and other legal representatives.


3. Each Assignor hereby constitutes and appoints Assignee as such Assignor's true and lawful attorney in fact, with full power of substitution in such Assignor's name and stead, to take any and all steps, including proceedings at law, in equity or otherwise, to execute, acknowledge, and deliver any and all instruments and assurances necessary or expedient in order to vest or perfect the aforesaid rights and related causes of action in the Assigned Trademarks more effectively in Assignee or to protect the same or to enforce any claim or right of any kind with respect thereto.
4. This Trademark Assignment is intended to evidence the closing of the Transactions contemplated by the Asset Purchase Agreement. Nothing contained in this Assignment shall be construed to supersede, limit or qualify any provision of the Asset Purchase Agreement. To the extent there is a conflict between the terms and provisions of this Trademark Assignment and the terms and provisions of the Asset Purchase Agreement, the terms and provisions of the Asset Purchase Agreement shall govern.
5. This Trademark Assignment may be executed in one or more counterparts, each of which shall be deemed an original, and all of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, *e.g.*, www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. In proving this Trademark Assignment, it shall not be necessary to produce or account for more than one such counterpart signed by the Party against whom enforcement is sought.

[Signature Page Follows]


IN WITNESS WHEREOF, the parties have caused this Trademark Assignment to be executed as of the day and year first above written.

ASSIGNOR

PLx Pharma Inc.


By: 
Name: Natasha Giordano
Title: President and Chief Executive Officer

PLx Opco Inc.

By: 
Name: Natasha Giordano
Title: President and Chief Executive Officer

ASSIGNEE

PLx Acquisition Company, LLC

By:  _____
Name: George Cleary
Title: Authorized Signatory

SCHEDULE A

Juris.	Mark	App. No.	App. Date	Reg. No.	Reg. Date
US	PLX PHARMA INC. Logo	90188918	September 17, 2020	6591723	December 14, 2021
US	ASPIRIN MADE AMAZING!	90546766	February 25, 2021	6810135	August 2, 2022
US	HEART PROTECTION WITH YOUR STOMACH IN MIND	90553277	March 1, 2021	6805044	July 26, 2022
US	Water swoosh - 325 mg	6782829	January 31, 2020	88780609	July 5, 2022
US	Water swoosh - 81 mg	6732291	January 30, 2020	88779671	May 24, 2022
US	ASPIRIN THERAPY VAZALORE & Design	90517922	February 8, 2021	6688135	March 29, 2022
US	FIRST LIQUID- FILLED ASPIRIN CAPSULES	88002473	June 15, 2018	6672405	March 15, 2022
US	VAZALORE	90157665	September 3, 2020	6591629	December 14, 2021
US	VAZALORE Logo & Heart Design	88756309	January 13, 2020	6591111	December 14, 2021
US	PLX	87072653	June 15, 2016	5128399	January 24, 2017
US	PLXGUARD	90165649	September 8, 2020		
US	Heart Design	88756336	January 13, 2020		
US	ASPIRIN FOR LIFE	90764540	June 9, 2021		